Supplemental Table 3.2a. Transition Probabilities for Eligible Cohort From 0 to 4 Months. Transition probabilities for the 8 potential states in the Markov model, as measured among all eligible individuals in the retrospective CD cohort.

Tx at Cohort Entry / Count Row Percent 95% CI	Total	Lost to Fup	Tx in Month 4							
			0: No Meds	1: CS	2: IFX	3: ADA	4: CTZ	5: IFX + CS	6: ADA + CS	7: CTZ + CS
1: CS	7841	375	3949	3014	127	40	7	68	25	3
			52.9	40.4	1.7	0.5	0.1	0.9	0.3	0.0
			51.8-54.0	39.3-41.5	1.4-2.0	0.4-0.7	0.0-0.2	0.7-1.2	0.2-0.5	0.0-0.1
2: IFX	985	64	156	34	618	7	2	67	2	0
			16.9	3.7	67.1	0.8	0.2	7.3	0.2	0.0
			14.6-19.5	2.6-5.1	64.0-70.1	0.3-1.6	0.0-0.8	5.7-9.1	0.0-0.8	0.0-0.4
3: ADA	290	4	48	5	1	187	2	1	26	1
			16.8	1.7	0.3	65.4	0.7	0.3	9.1	0.3
			12.6-21.6	0.6-4.0	0.0-1.9	59.6-70.9	0.1-2.5	0.0-1.9	6.0-13.0	0.0-1.9
4: CTZ	71	1	6	1	0	0	52	1	1	5
			8.6	1.4	0.0	0.0	74.3	1.4	1.4	7.1
			3.2-17.7	0.0-7.7	0.0-5.1	0.0-5.1	62.4-84.0	0.0-7.7	0.0-7.7	2.4-15.9
5: IFX + CS	428	14	55	28	222	7	0	78	1	1
			13.3	6.8	53.6	1.7	0.0	18.8	0.2	0.2
			10.2-16.9	4.5-9.6	48.7-58.5	0.7-3.5	0.0-0.9	15.2-22.9	0.0-1.3	0.0-1.3
6: ADA + CS	135	2	6	7	3	77	0	0	31	0
			4.5	5.3	2.3	57.9	0.0	0.0	23.3	0.0
			1.7-9.6	2.1-10.5	0.5-6.5	49.0-66.4	0.0-2.7	0.0-2.7	16.4-31.4	0.0-2.7

Tx at Cohort Entry						Tx in Month 4				
Count Row Percent 95% CI	Total	Lost to Fup	0: No Meds	1: CS	2: IFX	3: ADA	4: CTZ	5: IFX + CS	6: ADA + CS	7: CTZ + CS
7: CTZ + CS	30	0	2	1	1	1	18	0	0	4
			6.7	3.3	3.3	3.3	60.0	0.0	0.0	13.3
			0.8-22.1	0.1-17.2	0.1-17.2	0.1-17.2	40.6-77.3	0.0-11.6	0.0-11.6	3.8-30.7

ADA = Adalimumab; CS = corticosteroids; CTZ = Certolizumab; IFX = Infliximab; Tx = treatment. Gray shading denotes no change. Green shading denotes the most common transition when other than no change.